News Archive

GlaxoSmithKline is reportedly considering whether to split its business into a consumer health spin-off and standalone pharmaceutical and vaccines group.

U.S. Senator Tim Kaine (D-VA) today visited Vibrent Health, a Fairfax, Virginia-based health technology company for a tour of the company’s new office followed by a town hall session with Vibrent’s 140 employees.

“Studying and developing new technologies is critical to improving our health care system and expanding access to more Virginians. I’m looking forward to learning more about the work Vibrent Health is doing to modernize the industry as well as hearing from their employees on how the Senate can better support innovation in the health care space,” said Kaine.

Following an advisory panel recommendation on July 6, the US Food and Drug Administration has approved, under Priority Review, single-dose Krintafel (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax)malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.

Venture capital investment in early-stage biotechnology and pharmaceutical startups is seeing exuberance that could be classed as “froth,” but it does not appear to be in bubble territory yet.

Gaithersburg biotech startup Neuraly has raised $36 million for its potential Alzheimer’s disease and Parkinson’s disease treatment, the company announced.

IndieBio is making its way to New York.

The San Francisco-based biotech incubator received a $25 million investment from the state’s government. The move is part of a broader push to support life sciences startups across New York State (h/t The Wall Street Journal).

The University of Pennsylvania’s startup incubator is getting a boost from a big pharmaceutical company.

The First Coast Innovator’s Gathering on Day 1 is focused on tech hubs and companies from the First Coast: DC, MD, PA, NJ, NY, RI, CT, and MA. We encourage all global tech hubs and their constituents to attend.

There’s been more venture capital invested through the first six months of 2018 in the US than any six-month period in recent history, which highlights the new normal in the industry: more capital concentrated into fewer, larger deals. On the exit end of the spectrum, there’s been improved access to the IPO market, particularly for enterprise tech companies.